Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Bilateral Mastectomy
NCT05554211Phase 2Withdrawn
- Sponsor
- Northwestern University
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tranexamic acid in breast cancer and hereditary breast and ovarian cancer syndrome (HBOC) (2 arms), sponsored by Northwestern University. Primary endpoint: Drain output at 1 month. Planned start Jul 2022; status: withdrawn.
02
Drugs
tranexamic acid
03
Conditions
breast cancerhereditary breast and ovarian cancer syndrome (HBOC)
Beyond the preview
Go deeper on NCT05554211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554211.